Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors

Clinical data confirmed that patients with ROS1 rearrangement are sensitive to specific inhibitors like crizotinib. Therefore, reliable detection of ROS1 rearrangements is essential. Several diagnostic techniques are currently available. However, previous studies were hampered by the low number of ROS1 positive samples. Here, 35 samples, including 32 ROS1 fluorescent in situ hybridization (FISH) fusion positive and three ROS1 FISH negative samples were evaluated by ROS1 CISH, ROS1 immunohistochemistry (IHC), an Agilent SureSelect XT HS custom panel, the Archer FusionPlex CTL panel, and a custom NanoString fusion panel.

Source: Journal of Molecular Diagnostics - August 1, 2019 Category: Pathology Authors: Carina Heydt, Vanessa Ruesseler, Roberto Pappesch, Svenja Wagener, Anja Haak, Udo Siebolts, Richard Riedel, Sebastian Michels, Juergen Wolf, Anne M. Schultheis, Jan Rehker, Reinhard Buettner, Sabine Merkelbach-Bruse Source Type: research